Mechanisms of action of topical 5-fluorouracil: Review and implications for the treatment of dermatological disorders

Journal of Dermatological Treatment

Volumn 23, Issue 2, 2012, Pages 83-89

  Ceilley, Roger I ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Dermatology PC   (United States)

Author keywords

5 fluorouracil; Actinic keratosis; Keratoacanthoma; Mechanisms of action; Photoaging; Psoriasis; Skin cancer; Warts

Indexed keywords

CYTOKERATIN 16; DNA; FLUOROURACIL; GELATINASE B; GLYCOLIC ACID; IMIQUIMOD; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; PROCOLLAGEN; PROTEIN P53; STROMELYSIN; THYMIDINE PHOSPHATE;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; CELL PROLIFERATION; CRYOTHERAPY; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RETENTION; DRUG SELECTIVITY; HUMAN; KERATOACANTHOMA; PHOTOAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RNA INTERFERENCE; SKIN PERMEABILITY; SQUAMOUS CELL CARCINOMA; UPREGULATION; VERRUCA VULGARIS; VIRUS REPLICATION;

ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; SKIN DISEASES;

EID: 84858211182     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.507704     Document Type: Review

References (50)

1. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957; 179:663-666.
2. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381-395.
3. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-338. (Pubitemid 37328853)
4. Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat. 2009;20(6):328-335.
5. Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol. 1981;4:633-649. (Pubitemid 11037991)
6. Sachs DL, Kang S, Hammerberg C, Helfrich Y, Karimipour D, Orringer J, et al. Topical fluorouracil for actinic keratoses and photoaging: A clinical and molecular analysis. Arch Dermatol. 2009;145:659-666.
7. Rutman RJ, Cantarow A, Paschkis KE. Studies in 2-acetyla-minofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 1954;14:119-123.
8. Duschinsky R, Pleven E. The synthesis of 5-fluoropyrimi-dines. J Am Chem Soc. 1957;79:4559-4560.
9. Diasio RB, Harris BE. Clinical pharmacology of 5-fluoroura-cil. Clin Pharmacokinet. 1989;16:215-237.
10. Klein E, Helm F, Milgrom H, Stoll HL Jr, Traenkle HL. Tumors of the skin. II. Keratoacanthoma; local effect of 5-fluorouracil. Skin (Los Angeles). 1962;1:153-156.
11. Goldman L. The response of skin cancer to topical therapy with 5-fluorouracil. Cancer Chemother Rep. 1963;28:49-52.
12. Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol. 1963;88:247-256.
13. Snyderman RK, Starzynski TE. Treatment of skin cancers and keratoses with 5-fluorouracil. Acta Chir Plast. 1968;10: 181-187.
14. Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol. 1980;104:309-319. (Pubitemid 11127508)
15. Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem. 1987;262:8235-8241.
16. Mitrovski B, Pressacco J, Mandelbaum S, Erlichman C. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells. Cancer Chemother Pharmacol. 1994;35:109-114. (Pubitemid 24359730)
17. Aherne GW, Hardcastle A, Raynaud F, Jackman AL. Immu-noreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a non-polyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol. 1996; 51:1293-1301. (Pubitemid 26142854)
18. Ghoshal K, Jacob ST. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res. 1994;54:632-636. (Pubitemid 24068314)
19. Patton JR. Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry. 1993;32:8939-8944. (Pubitemid 23268819)
20. Doong SL, Dolnick BJ. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem. 1988;263: 4467-4473. (Pubitemid 18096631)
21. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15-16.
22. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res. 2002;62: 2644-2649. (Pubitemid 34462747)
23. Ju J, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res. 2007;13:4245-4251. (Pubitemid 47105989)
24. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999; 104:263-269.
25. McNutt NS, Saenz-Santamaria C, Volkenandt M, Shea CR, Albino AP. Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol. 1994;130:225-232. (Pubitemid 24056050)
26. Fluoroplex package insert. Irvine, CA: Allergan, Inc.; 2004.
27. Efudex package insert. Costa Mesa, CA: Valeant Pharmaceuticals North America; 2005.
28. Carac package insert. Bridgewater, NJ: Dermik Laboratories; August 2009.
29. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901-907. (Pubitemid 32554571)
30. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluoro-uracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000. (Pubitemid 34734743)
31. Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Further studies with topical 5-fluorouracil. Arch Dermatol. 1965;92: 410-417.
32. Erlanger M, Martz G, Ott F, Storck H, Rieder J, Kessler S. Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin. Dermatologica. 1970;140 (suppl I):7-14.
33. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006-2011. (Pubitemid 29399251)
34. Torres A. Non-surgical approaches to non-melanoma skin cancer. Presented at the Winter Clinical Dermatology Conference, 23-28 January 2010, Koloa, HI.
35. EaglsteinWH,WeinsteinGD,FrostP.Fluorouracil:Mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970;101:132-139.
36. Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis-A systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453-463.
37. Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140: 813-816. (Pubitemid 38917849)
38. Marrero GM, Katz BE. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol Surg. 1998;24:973-978. (Pubitemid 28453045)
39. Ditre CM. The treatment of photodamaged skin with 5% 5-fluorouracil peels. Cosmet Dermatol. 2007;20: 568-572. (Pubitemid 47573241)
40. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433-440.
41. Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 1978;114:1021-1022.
42. Gray RJ, Meland NB. Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg. 2000;44:82-85. (Pubitemid 30056303)
43. Yuge S. Keratoacanthoma centrifugum marginatum: Response to topical 5-fluorouracil. J Am Acad Dermatol. 2006;54:S218-S219.
44. Hadley JC, Tristani-Firouzi P, Florell SF, Bowen GM, Hadley ML. Case series of multiple recurrent reactive kera-toacanthomas developing at surgical margins. Dermatol Surg. 2009;35:2019-2024.
45. Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006;55:1092-1094. (Pubitemid 44716481)
46. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Der-matol. 2007;6:778-781.
47. Gibbs S, Harvey I. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2006;3:CD001781.
48. Salk RS, Grogan KA, Chang TJ. Topical 5% 5-fluorouracil cream in the treatment of plantar warts: A prospective, randomized, and controlled clinical study. J Drugs Dermatol. 2006;5:418-424.
49. De Jong EM, Menke HE, van Praag MC, van de Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatology. 1999;199:313-318. (Pubitemid 30009041)
50. Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol. 1962;74:229-236.